HBHans G. Beger

Hans G. Beger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hans G. Beger has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Laparoscopic duodenum-preserving pancreatic head resection in 459 patients for precancerous, cystic neoplasms, and neuroendocrine tumors. Perioperative outcome: systematic review and meta-analysis

    by Hans G. Beger, Yang Yinmo, Benjamin Mayer, Bertram Poch

    Background: With regard to laparoscopic approach, the objective arises whether standard multiorgan Whipple resection (PD) or parenchyma-sparing procedures (DPPHRt) are the most qualified surgical treatments for benign, premalignant neoplasms. Methods: Pubmed, Embase, Medline, and Cochrane Libraries were searched for studies reporting results and late outcomes after laparoscopic DPPHRt (L-DPPHRt) and laparoscopic PD (L-PD) for benign tumors. Data of 19 cohort studies including 459 patients were assessed. Results of six controlled trials comprising 129 L-DPPHRt and 205 L-PD for benign neoplasms were compared. Results: L-DPPHRt was performed for 123 IPMNs, 44 MCNs, 98 SPNs, 102 SCNs, and 59 PNETs. 90-day mortality was 2 of 459 patients (0.43%). Pancreatic fistula B / C occurred in 83 patients (18.08%) and biliary fistula in 35 patients (7.62%). Incidence of POPF B + C following complete and incomplete L-DPPHRt was 36/256 pats. (14.06%) and 40/167 pats. (23.95%) ( p = 0.030), respectively. LHS was 14.24 days (mean). Laparoscopic total DPPHR unveiled very low risk of hospital mortality (1/459 pats.;0.21%), reoperation (9/364 pats.;2.47%), DGE (14/280 pats.;5.0%), CBD stenosis (2/459 pats.;0.43%), and ischemic lesion of CBD (2/459 pats.;0.43%). Comparing 129 L-DPPHRt with 205 L-PD patients revealed overall mean values of 239. vs. 343 min. for OP time and 128 ml vs. 240 ml for estimated blood loss. Meta analysis using standardized mean difference (SMD) demonstrated these differences to be significant (OP time: SMD − 1.20, 95% CI − 2.08 to 0.31; p = 0.008; blood loss: SMD − 1.77, 95% CI − 2.87 to − 0.66; p = 0.002). L-DPPHRt was associated with better intraoperative and early postoperative performance. Conclusions: Laparoscopic DPPHR for cystic neoplasms and PNETs is a low-risk procedure leading to cure of patients. L-DPPHRt accomplishes the most appropriate goals for treatment of patients with benign, premalignant, cystic neoplasms, and PNETs (> 2 cm) of the pancreatic head.


  • Open Access

    Long-Term Oncologic Outcome following Duodenum-Preserving Pancreatic Head Resection for Benign Tumors, Cystic Neoplasms, and Neuroendocrine Tumors: Systematic Review and Meta-analysis

    by Hans G. Beger, Benjamin Mayer, Bertram Poch

    Background: Pancreatoduodenectomy (PD) has a considerable surgical risk for complications and late metabolic morbidity. Parenchyma-sparing resection of benign tumors has the potential to cure patients associated with reduced procedure-related short- and long-term complications. Materials and Methods: Pubmed, Embase, and Cochrane libraries were searched for studies reporting surgery-related complications following PD and duodenum-preserving total (DPPHRt) or partial (DPPHRp) pancreatic head resection for benign tumors. A total of 38 cohort studies that included data from 1262 patients were analyzed. In total, 729 patients underwent DPPHR and 533 PD. Results: Concordance between preoperative diagnosis of benign tumors and final histopathology was 90.57% for DPPHR. Cystic and neuroendocrine neoplasms (PNETs) and periampullary tumors (PATs) were observed in 497, 89, and 31 patients, respectively. In total, 34 of 161 (21.1%) patients with intraepithelial papillar mucinous neoplasm exhibited severe dysplasia in the final histopathology. The meta-analysis, when comparing DPPHRt and PD, revealed in-hospital mortality of 1/362 (0.26%) and 8/547 (1.46%) patients, respectively [OR 0.48 (95% CI 0.15–1.58); p = 0.21], and frequency of reoperation of 3.26 % and 6.75%, respectively [OR 0.52 (95% CI 0.28–0.96); p = 0.04]. After a follow-up of 45.8 ± 26.6 months, 14/340 patients with intraductal papillary mucinous neoplasms/mucinous cystic neoplasms (IPMN/MCN, 4.11%) and 2/89 patients with PNET (2.24%) exhibited tumor recurrence. Local recurrence at the resection margin and reoccurrence of tumor growth in the remnant pancreas was comparable after DPPHR or PD [OR 0.94 (95% CI 0.178–5.34); p = 0.96]. Conclusions: DPPHR for benign, premalignant neoplasms provides a cure for patients with low risk of tumor recurrence and significantly fewer early surgery-related complications compared with PD. DPPHR has the potential to replace PD for benign, premalignant cystic and neuroendocrine neoplasms.


  • Open Access

    Prämaligne, zystische Neoplasien und neuroendokrine Tumoren des Pankreaskopfes – Ist die Kausch-Whipple-Resektion eine adäquate Therapie?

    by Hans G. Beger

    Zusammenfassung: Das gegenwärtig am häufigsten angewendete operative Verfahren bei symptomatischen, benignen, prämalignen zystischen und neuroendokrinen Tumoren des Pankreaskopfs ist die Whipple-Operation oder pyloruserhaltende Pankreatoduodenektomie (PD); die PD ist jedoch eine Multiorganresektion, bei der pankreatisches und extrapankreatisches Gewebe sowie dessen Funktionen verloren gehen. Die PD ist auch bei benignen Neoplasien mit dem Risiko erheblicher Komplikationen in der frühen postoperativen Phase assoziiert und geht mit einer Krankenhausmortalität von bis zu 5 % einher. Nach Whipple-Operation wird bei 14–20 % der Patienten ein sich neu manifestierender Diabetes mellitus beobachtet, bei 25–45 % tritt eine exokrine Insuffizienz auf, was zu einer nach Resektion benigner Tumoren persistierenden metabolischen Dysfunktion und Beeinträchtigung der Lebensqualität führt. Symptomatische Neoplasien sind Indikation für die operative Therapie. Patienten mit asymptomatischen Pankreastumoren werden gemäß den Kriterien von Surveillance-Protokollen behandelt. Ziel der operativen Therapie bei asymptomatischen Patienten ist entsprechend den Leitlinienkriterien der Abbruch des Surveillance-Programms, bevor sich eine fortgeschrittene Krebserkrankung im Zusammenhang mit der Neoplasie entwickelt. Die Tumorenukleation und duodenumerhaltende Pankreaskopfresektion, entweder total oder partiell, sind parenchymsparende Resektionen bei benignen Neoplasien des Pankreaskopfs. Erste Wahl bei kleinen Tumoren ist die Enukleation; allerdings ist diese mit einem erhöhten Risiko für Pankreasfisteln von Grad B + C nach Pankreas-Hauptgangverletzung assoziiert. Vorteile der duodenumerhaltenden totalen oder partiellen Pankreaskopfresektion sind geringe operationsbedingte Komplikationen, eine Mortalität von < 0,5 % und die Aufrechterhaltung der endo- und exokrinen Pankreasfunktionen. Parenchymsparende Pankreaskopfresektionen sollten die klassischen Whipple-Operationen bei Neoplasien des Pankreaskopfs ablösen.


  • Open Access

    Whipple Resection for Benign Tumors and Premalignant Neoplasms of the Pancreatic Head: Surgery-Associated Risk for Complications and Late Metabolic Morbidity Matters

    by Hans G. Beger, Helmut Friess, Waldemar Uhl

    Benign and premalignant neoplasms of the pancreas are increasingly detected and recommended for surgical treatment. For tumors of the pancreatic head, the challenging decision is: multiorgan resection or local tumor extirpation? Compared with pancreaticoduodenectomy, duodenum-preserving pancreatic head resection is associated with significantly fewer surgery-related serious and severe complications and lower in-hospital mortality. The decisive advantage of duodenum-preserving pancreatic head resection is the maintenance of endocrine and exocrine pancreatic and upper gastrointestinal tract functions.


  • DUODENUM-PRESERVING PANCREATIC HEAD RESECTION FOR CHRONIC PANCREATITIS, BENIGN AND PREMALIGNANT TUMORS OF THE PANCREAS

    by G. Beger Hans, The University of Ulm, Endocrine And Minimally Invasive Surgery Center Of Oncology, Link Karl-Heinz, V.A. Asanovich, E.Ya. Nikolenko, E.A. Stradymov, A.I. Akperov, A.A. Rubtsov, Clinic Asklepios Paulinen, et al.

    Objective. To report the institutional experience of the evolution of duodenum-preserving pancreatic head resection (DPPHR) as a surgical treatment for chronic pancreatitis with an inflammatory tumor as well as cystic and benign, premalignant neoplasms and neuroendocrine tumors of the pancreatic head. Methods. DPPHR is associated with preservation of gastric antrum, common bile duct and duodenum/upper jejunal loop, contrary to Kausch-Whipple resection, which is a multivisceral procedure, including duodenectomy. Duodenum-preserving pancreatic head resection was first established in clinical setting in Berlin in 1969. Results. For chronic pancreatitis with an inflammatory infiltrat in the pancreatic head, duodenum-preserving pancreatic head resection has become a standard surgical treatment with worldwide acceptance. In a series of 603 patients with chronic pancreatitis following DPPHR, the frequency of pancreatic fistula was 3.3 %, intra-abdominal abscess 2.8 %, hemorrhage 2.8 %, frequency of reoperation 5.6%, in-hospital mortality 0.82 % and 90-day rehospitalisation 8 %. DPPHR for benign and premalignant cystic neoplasms of the pancreatic head is used predominantly for IPMN, MCN and SPN tumors. In a review of international publications comprising 503 patients, the general morbidity was 38.2 %, severe surgery-related complications 12.7% of them pancreatic fistula B+C 13.6 %, resurgery 2.7 % and 90-day mortality 0.4 %. When pancreatic neuroendocrine tumors of pancreatic head are treated with DPPHR, a local lymph node dissection is additionally recommended. The long-term morbidity following DPPHR revealed new onset of diabetes mellitus and exocrine dysfunctions in only 5-7 % of patients. Conclusion. Kausch-Whipple resection is associated with considerable high metabolic complications. Duodenum-sparing pancreatic head resection for inflammatory tumor, benign and premalignant neoplasms, and neuroendocrine tumors of the pancreatic head has the advantage of the duodenum preservation and maintenance of the pancreatic endocrine and exocrine functions.

  • Long-term Metabolic Morbidity and Steatohepatosis Following Standard Pancreatic Resections and Parenchyma-sparing, Local Extirpations for Benign Tumor

    by Hans G. Beger, Benjamin Mayer, Catalin Vasilescu, Bertram Poch

    Objective: To assess metabolic dysfunctions and steatohepatosis after standard and local pancreatic resections for benign and premalignant neoplasms. Summary of Background Data: Duodenopancreatectomy, hemipancreatectomy, and parenchyma-sparing, limited pancreatic resections are currently in use for nonmalignant tumors. Methods: Medline, Embase, and Cochrane libraries were searched for studies reporting measured data of metabolic functions following PD, pancreatic left resection (PLR), duodenum-sparing pancreatic head resection (DPPHR), pancreatic middle segment resection (PMSR), and tumor enucleation (TEN). Forty cohort studies comprising data of 2729 patients were eligible. Results: PD for benign tumor was associated in 46 of 327 patients (14.1%) with postoperative new onset of diabetes mellitus (pNODM) and in 109 of 243 patients (44.9%) with postoperative new onset of pancreatic exocrine insufficiency measured after a mean follow-up of 32 months. The meta-analysis displayed pNODM following PD in 32 of 204 patients (15.7%) and in 10 of 200 patients (5%) after DPPHR [P < 0.01; OR: 0.33; (95%-CI: 0.15–0.22)]. PEI was found in 77 of 174 patients following PD (44.3%) and in 7 of 104 patients (6.7%) following DPPHR (P < 0.01;OR: 0.15; 95%-CI: 0.07–0.32). pNODM following PLR was reported in 107 of 459 patients (23.3%) and following PMSR 23 of 412 patients (5.6%) (P < 0.01; OR: 0.20; 95%-CI: 0.12–0.32). Postoperative new onset of pancreatic exocrine insufficiency was found in 17% following PLR and in 8% following PMSR (P < 0.01). pNODM following PPPD and tumor enucleation was observed in 19.7% and 5.7% (P < 0.03) of patients, respectively. Following PD/PPPD, 145 of 608 patients (23.8%) developed a nonalcoholic fatty liver disease after a mean follow-up of 30.4 months. Steatohepatosis following DPPHR developed in 2 of 66 (3%) significantly lower than following PPPD (P < 0.01). Conclusion: Standard pancreatic resections for benign tumor carry a considerable high risk for a new onset of diabetes, pancreatic exocrine insufficiency and following PD for steatohepatosis. Parenchyma-sparing, local resections are associated with low grade metabolic dysfunctions.